Earnings call analysis

Stryker (SYK) Q3 2026 Earnings Call: Guidance and Outlook

Stryker provided updated full-year 2026 guidance, noting that they will not provide formal 2027 guidance until early next year.

About Stryker. Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries.

Call date

Oct 29, 2026

Sentiment score

+5 Cautious

Management tone, -100 to +100

Sentiment change

-20

vs Q2 2026 call

Sector

Health Care, Health Care Equipment and Supplies

Next report

Feb 4, 2027

View calendar

Quarterly guidance

Quarterly guidance: No quarterly guidance was given.

Annual guidance

Organic net sales growth: 6.5% to 7%
Adjusted net earnings per share: $14.80 to $14.90

Outlook

Hip and knee market: Management estimates market growth at approximately 2.5% for the year, citing economic pressures on patients.
Peripheral vascular: Inventory levels and product availability are expected to continue normalizing through the end of the year.
Capital demand: The order book remains strong and elevated across the portfolio.
2027 growth: Management expects to deliver growth at the high end of their markets.
Operational execution: The company is taking actions to improve competitive conversions and new product adoption following recent distractions.
SmartCare: The business had its best quarter in history and management expects continued momentum.

Sources and method

Dombey's summary of the Stryker Q3 2026 earnings call held Oct 29, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.

Updated Nov 9, 2026. All earnings call analyses

Research access

Research published before the catalyst, kept on the record after it.

Free AccountComplimentaryA DombeyAI account at no cost: the daily market view, earnings call analysis, a watchlist and every published pick tracked from the day it was named.Create a free account Standard Access$6.67 / monthOngoing catalyst coverage and the complete public-research archive, for readers who want to follow forthcoming events and revisit the firm's published thinking.Start Standard Access RecommendedFounding Membership$1,200 / yearInstitutional access to the complete research suite, proprietary models and execution strategy.Become a Founding Member